ScripIonis licensed global rights to Phase II polycythemia vera (PV) candidate sapablursen to Ono Pharmaceutical on 11 March. The deal provides near-term and longer-term revenue for a drug candidate the an
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January
ScripThe Jefferies London Healthcare Conference is now in its 15th year, and is firmly established as Europe’s biggest biopharma investment meeting. Here are some key themes to watch out for at the event,
ScripWhile Silence Therapeutics’ zerlasiran and Lilly’s muvalaplin produced high response rates in patients with elevated lipoprotein(a), or Lp(a), in Phase II trials, both candidates are coming in behind